Assessment of the effect of nano-curcumin oral intake on clinical signs and serum IL-6 levels in patients with ischemic stroke: Double-blind Clinical Trial
Phase 3
- Conditions
- Ischemic cerebral stroke.Stroke, non specified as haemorrhage or infarction
- Registration Number
- IRCT20091108002680N3
- Lead Sponsor
- Rasht University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Ischemic CVA less than 1 week from their symptoms begin
National Institutes of Health Stroke Scale (NIHSS) <= 20
Modified Rankin Scale (MRS) <= 4
Exclusion Criteria
Cerebral Venous Thrombosis
Hemorrhagic infarction
Internal capsule and Middle Cerebral Artery trunk infarction
History of gall bladder stone or bile duct stenosis
Gastroesophageal reflux disease or active peptic ulcer
Use of NSAIDs or Reserpine
Using anticoagulant or thrombolitic agent in last 24 hours
Using of Warfarin in last 1 week
Dissatisfaction
More than 1 week from symptoms begin
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Blood levels of inflammatory factor interleukin-6. Timepoint: Before treatment and after 1 month. Method of measurement: ELISA kit.
- Secondary Outcome Measures
Name Time Method